Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Penn Team Finds Molecular Relative of p53 Tumor Suppressor Protein also Helps Cancer Cells Thrive

17.07.2013
They say you can pick your friends, but not your family. The same may hold true for related proteins. The protein TAp73 is a relative of the well-known, tumor-suppressor protein p53.

It shares extensive common gene sequences with p53 and, as suggested by some previous studies, it may function similar to p53 to prevent tumor formation. However, unlike p53, which is the most commonly mutated gene in human tumors, TAp73 is rarely mutated, and instead is frequently overexpressed in a wide range of human tumors, including breast, colon, lung, stomach, ovarian, bladder, liver, neuroblastoma, glioma, and leukemias. In other words, cancer cells may have too many copies of the TAp73 gene.

Researchers still do not know whether TAp73 enhances tumor cell growth and, if so, exactly how it may give an advantage to tumor cells. But, in a new study that appears in Nature Cell Biology, Xiaolu Yang, PhD, professor of Cancer Biology at the Perelman School of Medicine, University of Pennsylvania, and the Abramson Family Cancer Research Institute, and colleagues found that TAp73 supports the proliferation of human and mouse tumor cells. They also identify an important mechanism by which TAp73 gives tumor cells a growth advantage: it activates the expression of an enzyme called glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting molecule of the pentose phosphate pathway (PPP).

To fuel the proliferation of tumor cells, their metabolic pathways are fundamentally reprogrammed. This reprogramming allows for rapid generation of macromolecules such as nucleic acids, lipids, and proteins. It also enables tumor cells to reduce the oxidative stresses they experience. The PPP is important for both biosynthesis and anti-oxidant defense, and tumor cells need this pathway for their high rate of replication.

The study was led by Peng Jiang, PhD, and Wenjing Du, PhD, two postdoctoral fellows in the Yang lab. They and the rest of the team found that by stimulating G6PD, TAp73 increases PPP activity and directs the sugar glucose to pathways for synthesizing macromolecules for replication and detoxifying reactive types of oxygen molecules to protect cells from harm.

The team also found that the decrease in replication in cells without TAp73 can be rescued by either enforced expression of G6PD, or adding basic molecules called nucleosides (the precursor for nucleic acids) and a reactive oxygen species scavenger to mop up these deleterious molecules, two outcomes of the PPP. These data provide the evidence that stimulating the PPP is a main proliferative effect of TAp73.

This is the first evidence that TAp73 is needed for tumor growth, as seen in the mouse and human colon, lung and other cancers studied.

Previous work by Yang’s lab, also led by Jiang and Du, found that p53 has the exact opposite effect on the PPP. They found that p53 physically binds to and inhibits G6PD. Through this inhibition, p53 normally dampens synthesis of molecules and cell reproduction by forcing the cell to take up less glucose. If p53 can't do its intended job, cells grow out of control. In tumors, more than half of which carry mutations in the p53 gene, this routing function is abolished, enabling cells to build biomass and divide with abandon. The opposing effect of two members of the p53 family on the G6PD underlines this importance of this enzymes and the pathway it controls, the PPP, in tumor cells.

“These findings establish a critical role for TAp73 in regulating metabolism and connect TAp73 and the PPP to cancerous cell growth,” says Yang.

The prevalence of p53 inactivation and TAp73 up-regulation indicate that modulating the pathways that these two proteins control could bring substantial benefit to tumor therapy. However, targeting these pathways has proven to be difficult as most proteins in the p53 and TAp73 pathway operate via protein-protein interactions, which are generally poor drug targets.

In contrast, metabolic enzymes are among the best drug targets. The identification of G6PD as an enzyme that becomes hyper-activate in tumors with p53 inactivation and/or TAp73 over-expression, two of the most common genetic alterations in cancer cells, suggests inhibition of this enzyme, or its related enzyme in the PPP pathway, may be highly beneficial for the therapy of a wide range of tumors.

The Yang lab has previously identified another set of enzymes that are both regulators and responders of p53. They hope that their work will give a strong impetus for developing high specific compounds for p53 and TAp73-regulated enzymes and testing them for cancer therapy, says Yang

This work was funded by the National Cancer Institute (CA088868 and GM060911) and the Department of Defense (W81XWH-10-1-0468) and grants from the University of Science and Technology of China.

Other co-authors include Anthony Mancuso, Aaron Stonestrom, Michael D. Brewer, Andy J. Minn, all from Penn, and Tak W. Mak, University of Toronto.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2012, Penn Medicine provided $827 million to benefit our community.

Karen Kreeger | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Life Sciences:

nachricht New yeast species discovered in Braunschweig, Germany
13.12.2019 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

nachricht Saliva test shows promise for earlier and easier detection of mouth and throat cancer
13.12.2019 | Elsevier

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Virus multiplication in 3D

Vaccinia viruses serve as a vaccine against human smallpox and as the basis of new cancer therapies. Two studies now provide fascinating insights into their unusual propagation strategy at the atomic level.

For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host’s nucleus can they find the machines,...

Im Focus: Cheers! Maxwell's electromagnetism extended to smaller scales

More than one hundred and fifty years have passed since the publication of James Clerk Maxwell's "A Dynamical Theory of the Electromagnetic Field" (1865). What would our lives be without this publication?

It is difficult to imagine, as this treatise revolutionized our fundamental understanding of electric fields, magnetic fields, and light. The twenty original...

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Supporting structures of wind turbines contribute to wind farm blockage effect

13.12.2019 | Physics and Astronomy

Chinese team makes nanoscopy breakthrough

13.12.2019 | Physics and Astronomy

Tiny quantum sensors watch materials transform under pressure

13.12.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>